Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00278889 | Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX) | PHASE2 | COMPLETED | 215 | — | — | Jan 1, 2006 | Oct 1, 2009 | Oct 24, 2012 | 43 | Austria, Belgium +7 |
Number of months from randomisation to the earlier date of objective progression or death
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | Bevacizumab + FOLFOX |
| 2 | EXPERIMENTAL | AZD2171 + FOLFOX |
| Name | Type | Description |
|---|---|---|
| AZD2171 | DRUG | oral tablet |
| 5-fluorouracil | DRUG | intravenous infusion |
| Leucovorin | DRUG | intravenous infusion |
| Oxaliplatin | DRUG | intravenous infusion |
| Bevacizumab | DRUG | intravenous infusion |
Inclusion Criteria: * Clinical diagnosis of colon or rectal cancer, * Received prior systemic therapy for cancer, * Cancer must have progressed during or after first treatment Exclusion Criteria: * Prior treatment with a VEGF inhibitor, * Poorly controlled hypertension